+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anti-Asthmatics And COPD Drugs Global Market Opportunities And Strategies To 2030: COVID 19 Implications and Growth

  • ID: 5021541
  • Report
  • April 2020
  • Region: Global
  • 319 Pages
  • The Business Research Company
1 of 6

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca plc.
  • Bristol Myers Squibb
  • F. Hoffmann-La Roche Ltd
  • KYORIN Holdings, Inc.
  • Neopharma
  • MORE

The "Anti-Asthmatics And COPD Drugs Global Market Opportunities And Strategies To 2030: COVID 19 Implications and Growth" report provides strategists, marketers and senior management with the critical information they need to assess the demand for anti-asthmatics and COPD drugs market which play a critical role in the treatment of patients with Covid 19.

Reasons to Purchase

  • Outperform competitors using accurate up to date demand-side dynamics information.
  • Understand how the market is experiencing rapid growth due to the coronavirus and how it is likely to stabilize as the impact of the virus abates.
  • Identify growth segments for investment.
  • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
  • Create regional and country strategies on the basis of local data and analysis.
  • Stay abreast of the latest customer and market research findings
  • Benchmark performance against key competitors.
  • Develop strategies based on likely future developments.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Gain a global perspective on the development of the market.

Description:

Where is the largest and fastest-growing market for the anti-asthmatics and COPD drugs market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The global anti-asthmatics and COPD drugs market opportunities and strategies to 2030: COVID 19 Implications and Growth report answers all these questions and many more.

The report covers the following chapters
1. Executive Summary –The executive summary section of the report gives a brief overview and summary of the report.
2. Report Structure – This section gives the structure of the report and the information covered in the various sections.
3. Introduction -The introduction section of the report gives brief introduction about segmentation by geography and segmentation by type.
4. Market Characteristics –The market characteristics section of the report defines and explains the anti-asthmatics and COPD drugs market. This chapter includes different goods covered in the report and basic definitions.
5. Supply Chain –The supply chain section of the report defines and explains the key players in the anti-asthmatics and COPD drugs industry supply chain.
6. Product Analysis –The product analysis section of the report describes the leading products in the market along with key features and differentiators for those products.
7. Top 10 Leading Drugs Sales–The section describes list of top 10 drugs and their sales in the anti-asthmatics and COPD drug market in 2019. It briefs on the drug chemical composition, drug class and the manufacturers involved in manufacturing and selling of these leading drugs in the anti-asthmatics and COPD drugs market.
8. Patent Analysis Of Leading Drugs–The section briefs on the patent analysis of the leading drugs in the anti-asthmatics and COPD drugs market, by focusing on the leading drugs’ patent expiry and emergence of the generic drugs in the market.
9. Customer Information– This chapter covers recent customers’ trends/preferences in the global anti-asthmatics and COPD drugs market.
10. Impact Of COVID-19- This section describes the impact of COVID-19 on the anti-asthmatics and COPD drugs market.
11. Trends And Strategies – This chapter describes the major trends shaping the global anti-asthmatics and COPD drugs market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
12. Asthma And COPD Prevalence Overview–This section describes about asthma and COPD and their prevalence in the major countries.
13. Global Market Size And Growth – This section contains the global historic (2015-2019) and forecast (2019 - 2023, 2025 and 2030) market values, and drivers and restraints that support and restrain the growth of the market in the historic and forecast periods.
14. Regional And Country Analysis – This section contains the historic (2015-2019), forecast (2023, 2025 and 2030) market value and growth and market share comparison by region and countries.
15. Market Segmentation –This section contains the market values (2015-2029, 2023, 2025 and 2030) and analysis for different segments in the market.
16. Regional Market Size And Growth–This section contains the region’s market size (2019), historic and forecast (2015-2019, 2023, 2025 and 2030) market values, and growth and market share comparison of major countries within the region. This report includes information on all the regions (Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa).
17. Competitive Landscape – This section covers details on the competitive landscape of the global anti-asthmatics and COPD drugs market, estimated market shares and company profiles of the leading players.
18. Key Mergers And Acquisitions – This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
19. Market Background – This section describes the respiratory diseases drugs market of which the anti-asthmatics and COPD drugs market is a segment. This chapter includes the respiratory diseases drugs market 2015-23 values, and regional analyses for the respiratory diseases drugs market.
20. Market Opportunities And Strategies– This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
21. Conclusions And Recommendations – This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for anti-asthmatics and COPD drugs providers in terms of product offerings, geographic expansion, price offerings, marketing strategies and target groups.
22. Appendix – This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered

By Type Of Drug Class: Combination Drugs; Bronchodilators; Monoclonal Antibodies; Anti-Inflammatory Drugs

By Type Of End-User: Asthma Patients; COPD Patients

By Distribution Channel: General Pharmacies; Hospital Pharmacies; Online Retailers

By Age Group: Below 5 Years; 5 to 14 Years; 15-69 Years; 70+ Years

By Type Of Therapy: Preventive; Curative

By Route Of Administration: Inhaled; Intravenous and Subcutaneous; Oral

By Type Of Prescription: Prescription; OTC

By Type Of Drug: Branded; Generics

Companies Mentioned: GlaxoSmithKline plc.; AstraZeneca plc.; Boehringer Ingelheim; F. Hoffmann-La Roche Ltd; Novartis

Countries: China, India, Japan, Australia, Indonesia, South Korea, USA, Russia, UK, Germany, France, Brazil.

Regions: Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Time-series: Two five-year periods, one three-year period and one six-year period.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca plc.
  • Bristol Myers Squibb
  • F. Hoffmann-La Roche Ltd
  • KYORIN Holdings, Inc.
  • Neopharma
  • MORE

1. Anti-Asthmatics And COPD Drugs Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction
6.1.1. Segmentation By Geography
6.1.2. Segmentation By Drug Class
6.1.3. Segmentation By End User
6.1.4. Segmentation By Distribution Channel
6.1.5. Segmentation By Therapy
6.1.6. Segmentation By Route Of Administration
6.1.7. Segmentation By Age Group
6.1.8. Segmentation By Prescription
6.1.9. Segmentation By Drug Type

7. Anti-Asthmatics And COPD Drugs Market Characteristics
7.1. Market Segmentation By Class
7.1.1. Bronchodilators
7.1.2. Anti-Inflammatory Drugs
7.1.3. Monoclonal Antibodies
7.1.4. Combination Drugs
7.2. Market Segmentation By End User
7.2.1. Asthma Patients
7.2.2. COPD Patients
7.3. Market Segmentation By Distribution Channel
7.3.1. Hospital Pharmacies
7.3.2. General Pharmacies
7.3.3. Online Retailers
7.4. Market Segmentation By Therapy
7.4.1. Preventive
7.4.2. Curative
7.5. Market Segmentation By Route Of Administration
7.5.1. Oral
7.5.2. Inhaled
7.5.3. Intravenous
7.5.4. Subcutaneous
7.6. Market Segmentation By Age Group
7.6.1. Below 5
7.6.2. 5-14
7.6.3. 15-60
7.6.4. Above 60
7.7. Market Segmentation By Prescription
7.7.1. Prescription
7.7.2. Over The Counter (OTC)
7.8. Market Segmentation By Drug Type
7.8.1. Branded
7.8.2. Generic

8. Anti-Asthmatics And COPD Drugs Market, Supply Chain Analysis
8.1.1. Raw Material And Equipment Procurement
8.1.2. Manufacturing, Processing and Packaging
8.1.3. Distribution
8.1.4. Physicians
8.1.5. End users

9. Anti-Asthmatics And COPD Drugs Market, Product Pipeline Analysis

10. Anti-Asthmatics And COPD Drugs Market, Top 10 Leading Drugs Sales
10.1.1. Ellipta
10.1.2. Spiriva
10.1.3. Symbicort
10.1.4. Advair
10.1.5. Pulmicort
10.1.6. Ventolin
10.1.7. Xolair
10.1.8. Nucala
10.1.9. Flovent
10.1.10. Fasenra

11. Anti-Asthmatics And COPD Drugs Market, Patent Analysis Of Leading Drugs
11.1.1. Background
11.1.2. Innovators

12. Anti-Asthmatics And COPD Drugs Market, Customer Information
12.1. Majority Of Australian COPD Patients Are Physically Inactive And Obese
12.2. Britons Experience Inadequate Treatment Of COPD
12.3. COPD Patients Are More Likely To Be Current Daily Smokers Or Ex-Smokers
12.4. Uncontrolled Asthma Patients Face Recurring Symptoms And Doctor Visits
12.5. Uncontrolled Asthma Patients Struggle With Mobility Issues

13. Impact of COVID-19 On The Anti-Asthmatics And COPD Drugs Market
13.1. Consumer Perception
13.2. High Mortality Among Asthma Patients
13.3. Anti-Asthmatic And COPD Drugs Used In COVID-19 Treatment

14. Anti-Asthmatics And COPD Drugs Market Regulatory Landscape
14.1.1. India
14.1.2. China
14.1.3. Japan
14.1.4. Australia
14.1.5. South Korea
14.1.6. Indonesia
14.1.7. USA
14.1.8. Canada
14.1.9. Mexico
14.1.10. UK
14.1.11. Germany
14.1.12. France
14.1.13. Russia
14.1.14. Brazil

15. Anti-Asthmatics And COPD Drugs Market Trends And Strategies
15.1. Collaborations In The Anti-Asthmatics and COPD Drugs Market
15.2. Increasing Demand For Personalized Medicines
15.3. Demand For Aerosol Respiratory Drugs
15.4. Use Of Biomarker For Precision Medicine
15.5. Rise Of Generic Respiratory Drugs
15.6. Combination Drug Therapy To Treat COPD
15.7.New Biologic Therapy Medicines To Treat Severe Asthma

16. Asthma And COPD Prevalence Overview
16.1. Asthma
16.2. COPD

17. Global Anti-Asthmatics And COPD Drugs Market Size And Growth
17.1. Market Size
17.2. Historic Market Growth, 2015 – 2019, Value ($ Million)
17.2.1. Historic Drivers Of The Market 2015-2019
17.2.2. Historic Restraints Of The Market 2015-2019
17.3. Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
17.3.1. Forecast Drivers Of The Market 2019-2023
17.3.2. Forecast Restraints Of The Market 2019-2023

18. Anti-Asthmatics And COPD Drugs Market, Regional And Country Analysis
18.1. Global Anti-Asthmatics And COPD Drugs Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
18.2. Global Anti-Asthmatics And COPD Drugs Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

19. Global Anti-Asthmatics And COPD Drugs Market Segmentation
19.1. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
19.1.1. Combination Drugs
19.1.2. Bronchodilators
19.1.3. Monoclonal Antibodies
19.1.4. Anti-Inflammatory Drugs
19.2. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
19.2.1. Asthma Patients
19.2.2. COPD Patients
19.3. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
19.3.1. General Pharmacies
19.3.2. Hospital Pharmacies
19.3.3. Online Retailers
19.4. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Therapy, 2019, Value ($ Million)
19.4.1. Preventive
19.4.2. Curative
19.5. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Route Of Administration, 2019, Value ($ Million)
19.5.1. Inhaled
19.5.2. Intravenous and Subcutaneous
19.5.3. Oral
19.6. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Patients’ Age Group, 2019, Value ($ Million)
19.6.1. 15-69 Years
19.6.2. 70+ Years
19.6.3. Below 5 Years
19.7. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Type Of Prescription, 2019, Value ($ Million)
19.7.1. Prescription
19.7.2. OTC
19.8. Global Anti-Asthmatics And COPD Drugs Market, Segmentation By Type Of Drug, 2019, Value ($ Million)
19.8.1. Branded
19.8.2. Generics

20. Asia-Pacific Anti-Asthmatics And COPD Drugs Market
20.1. Asia-Pacific Anti-Asthmatics And COPD Drugs Market Overview
20.1.1. Region Information
20.1.2. Market Information
20.1.3. Background Information
20.1.4. Government Initiatives
20.1.5. New Drug Trials And Approvals
20.1.6. Major Associations
20.1.7. Taxes Levied
20.1.8. Investments
20.1.9. Major Companies
20.2. Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
20.3. Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
20.4. Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
20.5. Asia-Pacific Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
20.6. Asia-Pacific Anti-Asthmatics And COPD Drugs Market: Country Analysis
20.7. China Anti-Asthmatics And COPD Drugs Market
20.8. China Anti-Asthmatics And COPD Drugs Market Overview
20.8.1. Country Information
20.8.2. Market Information
20.8.3. Background Information
20.8.4. Government Initiatives
20.8.5. New Drug Trials And Approvals
20.8.6. Major Associations
20.8.7. Taxes Levied
20.8.8. Investments
20.8.9. Major Companies
20.9. China Anti-Asthmatics And COPD Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
20.10. China Anti-Asthmatics And COPD Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
20.11. China Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
20.12. China Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
20.13. India Anti-Asthmatics And COPD Drugs Market
20.14. India Anti-Asthmatics And COPD Drugs Market Overview
20.14.1. Country Information
20.14.2. Market Information
20.14.3. Background Information
20.14.4. Government Initiatives
20.14.5. Major Associations
20.14.6. Taxes Levied
20.14.7. Investments
20.14.8. Major Companies
20.15. India Anti-Asthmatics And COPD Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
20.16. India Anti-Asthmatics And COPD Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
20.17. India Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
20.18. India Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
20.19. Japan Anti-Asthmatics And COPD Drugs Market
20.20. Japan Anti-Asthmatics And COPD Drugs Market Overview
20.20.1. Country Information
20.20.2. Market Information
20.20.3. Background Information
20.20.4. Government Initiatives
20.20.5. New Drug Trials And Approvals
20.20.6. Major Associations
20.20.7. Taxes Levied
20.20.8. Investments
20.20.9. Major Companies
20.21. Japan Anti-Asthmatics And COPD Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
20.22. Japan Anti-Asthmatics And COPD Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
20.23. Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
20.24. Japan Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
20.25. Australia Anti-Asthmatics And COPD Drugs Market
20.26. Australia Anti-Asthmatics And COPD Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
20.27. Australia Anti-Asthmatics And COPD Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
20.28. Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
20.29. Australia Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
20.30. Indonesia Anti-Asthmatics And COPD Drugs Market
20.31. Indonesia Anti-Asthmatics And COPD Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
20.32. Indonesia Anti-Asthmatics And COPD Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
20.33. Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
20.34. Indonesia Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
20.35. South Korea Anti-Asthmatics And COPD Drugs Market
20.36. South Korea Anti-Asthmatics And COPD Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
20.37. South Korea Anti-Asthmatics And COPD Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
20.38. South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
20.39. South Korea Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

21. Western Europe Anti-Asthmatics And COPD Drugs Market
21.1. Western Europe Anti-Asthmatics And COPD Drugs Market Overview
21.1.1. Region Information
21.1.2. Market Information
21.1.3. Background Information
21.1.4. Government Initiatives
21.1.5. New Drug Trials And Approvals
21.1.6. Major Associations
21.1.7. Taxes Levied
21.1.8. Major Companies
21.2. Western Europe Anti-Asthmatics And COPD Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
21.3. Western Europe Anti-Asthmatics And COPD Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
21.4. Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
21.5. Western Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
21.6. Western Europe Anti-Asthmatics And COPD Drugs Market: Country Analysis
21.7. UK Anti-Asthmatics And COPD Drugs Market
21.8. UK Anti-Asthmatics And COPD Drugs Market Overview
21.8.1. Country Information
21.8.2. Market Information
21.8.3. Background Information
21.8.4. Government Initiatives
21.8.5. New Drug Trials And Approvals
21.8.6. Major Associations
21.8.7. Taxes Levied
21.8.8. Major Companies
21.9. UK Anti-Asthmatics And COPD Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
21.10. UK Anti-Asthmatics And COPD Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
21.11. UK Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
21.12. UK Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
21.13. Germany Anti-Asthmatics And COPD Drugs Market
21.14. Germany Anti-Asthmatics And COPD Drugs, Historic Market Growth, 2015 – 2019, Value ($ Million)
21.15. Germany Anti-Asthmatics And COPD Drugs, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
21.16. Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
21.17. Germany Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
21.18. France Anti-Asthmatics And COPD Drugs Market
21.19. France Anti-Asthmatics And COPD Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
21.20. France Anti-Asthmatics And COPD Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
21.21. France Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
21.22. France Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

22. Eastern Europe Anti-Asthmatics And COPD Drugs Market
22.1. Eastern Europe Anti-Asthmatics And COPD Drugs Market Overview
22.1.1. Region Information
22.1.2. Market Information
22.1.3. Background Information
22.1.4. New Drug Trials And Approvals
22.1.5. Major Associations
22.1.6. Taxes Levied
22.1.7. Major Companies
22.2. Eastern Europe Anti-Asthmatics And COPD Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
22.3. Eastern Europe Anti-Asthmatics And COPD Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
22.4. Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
22.5. Eastern Europe Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
22.6. Russia Anti-Asthmatics And COPD Drugs Market
22.7. Russia Anti-Asthmatics And COPD Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
22.8. Russia Anti-Asthmatics And COPD Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
22.9. Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
22.10. Russia Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

23. North America Anti-Asthmatics And COPD Drugs Market
23.1. North America Anti-Asthmatics And COPD Drugs Market Overview
23.1.1. Region Information
23.1.2. Market Information
23.1.3. Background Information
23.1.4. Government Initiatives
23.1.5. New Drug Trials And Approvals
23.1.6. Major Associations
23.1.7. Taxes Levied
23.1.8. Investments
23.1.9. Major Companies
23.2. North America Anti-Asthmatics And COPD Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
23.3. North America Anti-Asthmatics And COPD Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
23.4. North America Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
23.5. North America Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
23.6. North America Anti-Asthmatics And COPD Drugs Market: Country Analysis
23.7. USA Anti-Asthmatics And COPD Drugs Market
23.8. USA Anti-Asthmatics And COPD Drugs Market Overview
23.8.1. Country Information
23.8.2. Market Information
23.8.3. Background Information
23.8.4. Government Initiatives
23.8.5. Major Associations
23.8.6. Taxes Levied
23.8.7. Investments
23.8.8. Major Companies
23.9. USA Anti-Asthmatics And COPD Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
23.10. USA Anti-Asthmatics And COPD Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
23.11. USA Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
23.12. USA Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

24. South America Anti-Asthmatics And COPD Drugs Market
24.1. South America Anti-Asthmatics And COPD Drugs Market Overview
24.1.1. Region Information
24.1.2. Market Information
24.1.3. Background Information
24.1.4. Major Associations
24.1.5. Government Initiatives
24.1.6. Investments
24.1.7. Major Companies
24.2. South America Anti-Asthmatics And COPD Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
24.3. South America Anti-Asthmatics And COPD Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
24.4. South America Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
24.5. South America Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
24.6. South America Anti-Asthmatics And COPD Drugs Market: Country Analysis
24.7. Brazil Anti-Asthmatics And COPD Drugs Market
24.8. Brazil Anti-Asthmatics And COPD Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
24.9. Brazil Anti-Asthmatics And COPD Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
24.10. Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
24.11. Brazil Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

25. Middle East Anti-Asthmatics And COPD Drugs Market
25.1. Middle East Anti-Asthmatics And COPD Drugs Market Overview
25.1.1. Region Information
25.1.2. Market Information
25.1.3. Background Information
25.1.4. Government Initiatives
25.1.5. Major Associations
25.1.6. Taxes Levied
25.1.7. Major Companies
25.2. Middle East Anti-Asthmatics And COPD Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
25.3. Middle East Anti-Asthmatics And COPD Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
25.4. Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
25.5. Middle East Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

26. Africa Anti-Asthmatics And COPD Drugs Market
26.1. Africa Anti-Asthmatics And COPD Drugs Market Overview
26.1.1. Region Information
26.1.2. Market Information
26.1.3. Background Information
26.1.4. Government Initiatives
26.1.5. Major Associations
26.1.6. Taxes Levied
26.1.7. Investments
26.1.8. Major Companies
26.2. Africa Anti-Asthmatics And COPD Drugs Market, Historic Market Growth, 2015 – 2019, Value ($ Million)
26.3. Africa Anti-Asthmatics And COPD Drugs Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)
26.4. Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By Drug Class, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)
26.5. Africa Anti-Asthmatics And COPD Drugs Market, Segmentation By End Users, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

27. Global Anti-Asthmatics And COPD Drugs Market Competitive Landscape
27.1. Company Profiles
27.2. GlaxoSmithKline plc.
27.2.1. Company Overview
27.2.2. Products And Services
27.2.3. Business Strategy
27.2.4. Financial Overview
27.3. AstraZeneca plc.
27.3.1. Company Overview
27.3.2. Products And Services
27.3.3. Business Strategy
27.3.4. Financial Overview
27.4. Boehringer-Ingelheim GmbH
27.4.1. Company Overview
27.4.2. Products And Services
27.4.3. Business Strategy
27.4.4. Financial Overview
27.5. F. Hoffmann-La Roche Ltd
27.5.1. Company Overview
27.5.2. Products And Services
27.5.3. Business Strategy
27.5.4. Financial Overview
27.6. Novartis AG
27.6.1. Company Overview
27.6.2. Products And Services
27.6.3. Business Strategy
27.6.4. Financial Overview

28. Key Mergers And Acquisitions In The Anti-Asthmatics And COPD Drugs Market
28.1. AptarGroup, Inc. Acquired Nanopharm Ltd and Gateway Analytical
28.2. ResMed Acquired Propeller Health
28.3. Circassia Acquired AstraZeneca’s COPD Treatment Tudorza
28.4. RecipharmAB Acquired Sanofi’s Inhalation Contract Manufacturing Business
28.5. Mast Therapeutics, Inc. Merged With Savara Inc.
28.6. Mylan N.V. Acquired Majority Stake In Meda AB
28.7. Vectura Group Merged With Skyepharma
28.8. Recordati Acquired Italchimici S.p.A.
28.9. Ruthigen, Inc. Merged With Pulmatrix, Inc.

29. Market Background: Respiratory Diseases Drugs Market
29.1. Respiratory Diseases Drugs Market Characteristics
29.1.1. Market Definition
29.1.2. Segmentation By Type
29.1.3. Anti-Asthmatics And COPD Drugs
29.1.4. Cough And Cold Preparations
29.2. Global Respiratory Diseases Drugs Market, Segmentation By Type, 2015 – 2023, Value ($ Billion)
29.3. Global Respiratory Diseases Drugs Market, 2019, By Region, Value ($ Billion)
29.4. Global Respiratory Diseases Drugs Market, 2015 – 2023, Historic And Forecast, By Region

30. Anti-Asthmatics And COPD Drugs Market Opportunities And Strategies
30.1. Global Anti-Asthmatics And COPD Drugs Market In 2023 – Countries Offering Most New Opportunities
30.2. Global Anti-Asthmatics And COPD Drugs Market In 2023- Segments Offering Most New Opportunities
30.3. Global Anti-Asthmatics And COPD Drugs Market In 2023 – Growth Strategies
30.3.1. Market Trend Based Strategies
30.3.2. Competitor Strategies

31. Global Anti-Asthmatics And COPD Drugs Market Recommendations
31.1. Conclusions
31.2. Recommendations
31.2.1. Product
31.2.2. Place
31.2.3. Price
31.2.4. Promotion

32. Appendix
32.1. Market Data Sources
32.2. Research Methodology
32.3. Currencies
32.4. Research Inquiries
32.5. About the Publisher
32.6. Copyright and Disclaimer

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Abbott Laboratories
  • AstraZeneca plc.
  • Bristol Myers Squibb
  • F. Hoffmann-La Roche Ltd
  • KYORIN Holdings, Inc.
  • Neopharma
  • MORE

This report describes and evaluates the global anti-asthmatics and COPD drugs market. It covers two five-year periods, one three-year period, and one six-year period including, 2015 to 2019, termed the historic period, and 2019 to 2023 forecast period, 2023-2025 forecast period and 2025 -2030 the forecast period.

The global anti-asthmatics and COPD drugs market reached a value of nearly $40,162.1 million in 2019, having grown at a compound annual growth rate (CAGR) of 4.4% since 2015. The global anti-asthmatics and COPD drugs market is expected to grow from $40,162.1 million in 2019 to about $49,384.3 million in 2020 due to an increase in demand for the use of anti-asthmatics and COPD drugs in the treatment of Covid-19 patients. The global anti-asthmatics and COPD drugs market is expected to grow at a CAGR of 4.1% to nearly $47,176.2 million by 2023. Also, the market is expected to grow to $51,164.1 million in 2025 at a CAGR of 4.1% and to $63,579.9 million in 2030 at a CAGR of 4.4%.

Growth in the historic period resulted from increased prevalence of respiratory diseases, increasing incidence of tobacco smoking, global warming, geriatric population, new methods for drug discovery, and rise in healthcare expenditure. Factors that negatively affected growth in the historic period were expiration of patents and political uncertainties.

Going forward, the increased popularity of e-cigarettes/vaping, rising obesity levels, technology, large pool of undiagnosed population, use of anti-asthmatics and COPD drugs to treat COVID-19 patients, and increasing consumption of fats are expected to drive the market. Factors that could hinder the growth of the anti-asthmatics and COPD drugs market in the future include side effects associated with respiratory drugs, reduction in free trade, and stringent regulations.

The anti-asthmatics and COPD drugs market is segmented by type of drug class into combination drugs, bronchodilators, monoclonal antibodies, and anti-inflammatory drugs. The combination drugs market was the largest segment of the anti-asthmatics and COPD drugs market by drug class, accounting for $14,964.9 million or 37.3% of the total market in 2019. The monoclonal antibodies market is expected to be the fastest-growing segment going forward at a CAGR of 7.4%.

The anti-asthmatics and COPD drugs market is segmented by type of end-user into asthma patients, and COPD patients. The asthma patients was the largest segment of the anti-asthmatics and COPD drugs market by end-user, accounting for $ 24,791.3 million or 61.7% of the total market in 2019. The COPD patients market is expected to be the fastest-growing segment going forward at a CAGR of 4.5%.

The anti-asthmatics and COPD drugs market is segmented by distribution channel into general pharmacies, hospital pharmacies, and online retailers. The general pharmacies was the largest segment of the anti-asthmatics and COPD drugs market by distribution channel, accounting for $ 26,424.3 million or 65.8% of the total market in 2019. The online retailers market is expected to be the fastest-growing segment going forward at a CAGR of 9.6%.

The anti-asthmatics and COPD drugs market is segmented by age group into below 5 years, 5 to 14 years, 15-69 years, and 70+ years. The 15-69 years age group was the largest segment of the anti-asthmatics and COPD drugs market by age group, accounting for $20,220.7 million or 50.3% of the total market in 2019.

The anti-asthmatics and COPD drugs market is segmented by therapy into preventive, and curative. The preventive was the largest segment of the anti-asthmatics and COPD drugs market by therapy, accounting for $21,791.0 million or 54.3% of the total market in 2019.

The anti-asthmatics and COPD drugs market is segmented by route of administration into inhaled, intravenous and subcutaneous, and oral. The inhaled was the largest segment of the anti-asthmatics and COPD drugs market by route of administration, accounting for $29,360.8 million or 73.1% of the total market in 2019.

The anti-asthmatics and COPD drugs market is segmented by prescription into prescription and OTC. The prescription was the largest segment of the anti-asthmatics and COPD drugs market by prescription, accounting for $37,521.9 million or 93.4% of the total market in 2019.

The anti-asthmatics and COPD drugs market is segmented by drug type into branded, and generics. The branded was the largest segment of the anti-asthmatics and COPD drugs market by drug type, accounting for $38,378.9 million or 95.6% of the total market in 2019.

North America was the largest region in the anti-asthmatics and COPD drugs market, accounting for 47.7% of the global market in 2019. It was followed by Asia Pacific, Western Europe and the other regions. Going forward, the fastest growing regions in the anti-asthmatics and COPD drugs market will be Asia-Pacific and the Middle East, where growth will be at CAGRs of 8.1% and 5.7% respectively from 2019-2023.

The global anti-asthmatics and COPD drugs market is consolidated, with a small number of large players. The top ten competitors in the market made up to 64.6% of the total market in 2019. Major players in the market include GlaxoSmithKline plc., AstraZeneca plc., Boehringer Ingelheim, F. Hoffmann-La Roche Ltd, Novartis and others.

COVID-19 is an infectious disease caused by a newly discovered coronavirus. COVID-19 which originated in the Wuhan Province of China, in December 2019 has now spread across the world. The unprecedented outbreak of coronavirus has caused a surge in demand for anti-asthmatics and COPD drugs as some anti-asthmatics and COPD drugs such as albuterol are being used in the treatment of COVID. With governments across the world advising people to practice social distancing, individuals are stocking up anti-asthmatics and COPD medications, increasing the demand for these drugs.

The top growth potential in the anti-asthmatics and COPD drugs market by drug class will arise in combination drugs market, which will gain $2,789.8 million of global annual sales by 2023. The top growth potential in the anti-asthmatics and COPD drugs market by end-user will arise in the asthma patients market, which will gain $4,060.0 million of global annual sales by 2023. The top growth potential in the anti-asthmatics and COPD drugs market by distribution channel will arise in general pharmacies market, which will gain $3,593.2 million of global annual sales by 2023. The anti-asthmatics and COPD drugs market size will gain the most in the USA at $2,283.6 million. Market-trend-based strategies for the anti-asthmatics and COPD drugs market include focusing on increasing the number of collaborations to expand business portfolios, investing in aerosol respiratory drugs for better efficacy, investing in biomarkers to produce more effective drugs in a smaller time frame, investing in generic drugs to counter the intense competition, developing combination drugs, and developing biologics. Player-adopted strategies in the anti-asthmatics and COPD drugs industry include investing in scientific and technical excellence to develop and launch a pipeline of new products, strengthening anti-asthmatics and COPD drugs business through the expansion of product portfolio, and expanding business through strategic investments focusing on expansion of manufacturing operations.

To take advantage of the opportunities, the publisher recommends the anti-asthmatics and COPD drugs companies to focus on personalized medicines, focus on increasing the production temporarily during the COVID-19 pandemic, leverage e-commerce to maximize reach and revenues, provide competitively priced offerings in low-income countries to reach new users, and focus on increasing awareness on asthma and COPD.

Note: Product cover images may vary from those shown
5 of 6
  • Abbott Laboratories
  • Ache
  • Adcock Ingram
  • Apotex Inc.
  • ASGEN Pharmaceutical Co., Ltd.
  • Aspen Nigeria
  • AstraZeneca plc.
  • Aurobindo Pharma Limited
  • Bayer
  • Biolab Farmaceuticad
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Chiesi Farmaceutici S.p.A.
  • China Meheco Group Co., Ltd
  • China National Pharmaceutical Group Co., Ltd. (Sinopharm)
  • Cipla Limited
  • Cipla Medpro South Africa (Pty) Limited
  • Cristalia
  • Daewoong Pharmaceutical Co., Ltd.
  • EMS Pharma
  • Eurofarma
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc.
  • Hanmi Pharmaceutical
  • Hypermarcas
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Julphar
  • KYORIN Holdings, Inc.
  • Libbs
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan
  • Neopharma
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Novartis
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer
  • Sanofi S.A.
  • Shanghai Acebright Pharmaceuticals Group Co., Ltd.
  • Shanghai Anovent Pharma
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Teva Pharmaceutical Industries Limited
  • Vectura Group
Note: Product cover images may vary from those shown
6 of 6

Loading
LOADING...

Adroll
adroll